It also provides strong evidence that the molecular targeting of BCL2, combined with crizotinib treatment, could widen the therapeutic options for these patients and potentially improve their outcomes, by reducing the options for cancer cell escape routes (Figure 1). This evidence concerns the gene BCL2 and cancer.